Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 5689709, 17 pages
https://doi.org/10.1155/2017/5689709
Research Article

Immunization with Bivalent Flagellin Protects Mice against Fatal Pseudomonas aeruginosa Pneumonia

1Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
2Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
3Burn Research Center, Hazrat Fatima Hospital, Iran University of Medical Sciences, Tehran, Iran
4Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
5Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Abbas Ali Imani Fooladi; moc.liamg@a.idaluofinami

Received 6 January 2017; Revised 25 August 2017; Accepted 10 September 2017; Published 19 October 2017

Academic Editor: Peirong Jiao

Copyright © 2017 Bahador Behrouz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. H. Gilligan, “Infections in patients with cystic fibrosis: diagnostic microbiology update,” Clinics in Laboratory Medicine, vol. 34, no. 2, pp. 197–217, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Safdar, C. Dezfulian, H. R. Collard, and S. Saint, “Clinical and economic consequences of ventilator-associated pneumonia: a systematic review,” Critical Care Medicine, vol. 33, no. 10, pp. 2184–2193, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. B. K. Chan, M. Sistrom, J. E. Wertz, K. E. Kortright, D. Narayan, and P. E. Turner, “Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa,” Scientific Reports, vol. 6, p. 26717, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. M. W. Douglas, K. Mulholland, V. Denyer, and T. Gottlieb, “Multi-drug resistant Pseudomonas aeruginosa outbreak in a burns unit—an infection control study,” Burns : Journal of the International Society for Burn Injuries, vol. 27, no. 2, pp. 131–135, 2001. View at Google Scholar
  5. M. Mudau, R. Jacobson, N. Minenza et al., “Outbreak of multi-drug resistant Pseudomonas aeruginosa bloodstream infection in the haematology unit of a South African academic hospital,” PLoS One, vol. 8, no. 3, article e55985, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. G. B. Pier, “Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen,” Carbohydrate Research, vol. 338, no. 23, pp. 2549–2556, 2003. View at Google Scholar
  7. E. T. Weimer, H. Lu, N. D. Kock, D. J. Wozniak, and S. B. Mizel, “A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa,” Infection and Immunity, vol. 77, no. 6, pp. 2356–2366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Sawa, T. L. Yahr, M. Ohara et al., “Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury,” Nature Medicine, vol. 5, no. 4, pp. 392–398, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. W. Wu, J. Huang, B. Duan et al., “Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia,” American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 5, pp. 420–427, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. G. P. Priebe, R. L. Walsh, T. A. Cederroth et al., “IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa,” Journal of Immunology, vol. 181, no. 7, pp. 4965–4975, 2008. View at Google Scholar
  11. J. Haiko and B. Westerlund-Wikstrom, “The role of the bacterial flagellum in adhesion and virulence,” Biology, vol. 2, no. 4, pp. 1242–1267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. H. C. Ramos, M. Rumbo, and J. C. Sirard, “Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa,” Trends in Microbiology, vol. 12, no. 11, pp. 509–517, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Hayashi, K. D. Smith, A. Ozinsky et al., “The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5,” Nature, vol. 410, no. 6832, pp. 1099–1103, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. S. K. Gupta, P. Bajwa, R. Deb, M. M. Chellappa, and S. Dey, “Flagellin a toll-like receptor 5 agonist as an adjuvant in chicken vaccines,” Clinical and Vaccine Immunology : CVI, vol. 21, no. 3, pp. 261–270, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Delavari, M. Sohrabi, M. S. Ardestani et al., “Pseudomonas aeruginosa flagellin as an adjuvant: superiority of a conjugated form of flagellin versus a mixture with a human immunodeficiency virus type 1 vaccine candidate in the induction of immune responses,” Journal of Medical Microbiology, vol. 64, no. 11, pp. 1361–1368, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. E. T. Weimer, S. E. Ervin, D. J. Wozniak, and S. B. Mizel, “Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonasaeruginosa,” Vaccine, vol. 27, no. 48, pp. 6762–6769, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Drake and T. C. Montie, “Protection against Pseudomonas aeruginosa infection by passive transfer of anti-flagellar serum,” Canadian Journal of Microbiology, vol. 33, no. 9, pp. 755–763, 1987. View at Publisher · View at Google Scholar
  18. H. Ochi, H. Ohtsuka, S. Yokota et al., “Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies against flagella of Pseudomonas aeruginosa,” Infection and Immunity, vol. 59, no. 2, pp. 550–554, 1991. View at Google Scholar
  19. M. J. Rosok, M. R. Stebbins, K. Connelly, M. E. Lostrom, and A. W. Siadak, “Generation and characterization of murine antiflagellum monoclonal antibodies that are protective against lethal challenge with Pseudomonas aeruginosa,” Infection and Immunity, vol. 58, no. 12, pp. 3819–3828, 1990. View at Google Scholar
  20. B. Behrouz, M. Mahdavi, N. Amirmozafari et al., “Immunogenicity of Pseudomonas aeruginosa recombinant b-type fagellin as a vaccine candidate: protective efficacy in a murine burn wound sepsis model,” Burns : Journal of the International Society for Burn Injuries, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Ahmadi, B. Behrouz, G. Irajian, N. Amirmozafari, and S. Naghavi, “Bivalent flagellin immunotherapy protects mice against Pseudomonas aeruginosa infections in both acute pneumonia and burn wound models,” Biologicals : Journal of the International Association of Biological Standardization, vol. 46, pp. 29–37, 2017. View at Publisher · View at Google Scholar
  22. M. Saffari, S. Behbood, G. Irajian, A. Khorshidi, R. Moniri, and B. Behrouz, “Antibodies raised against divalent type b flagellin and pilin provide effective immunotherapy against Pseudomonas aeruginosa infection of mice with burn wounds,” Biologicals : Journal of the International Association of Biological Standardization, vol. 45, pp. 20–26, 2017. View at Publisher · View at Google Scholar
  23. V. L. Campodonico, N. J. Llosa, M. Grout, G. Doring, T. Maira-Litran, and G. B. Pier, “Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines,” Infection and Immunity, vol. 78, no. 2, pp. 746–755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Kumar, L. D. Hazlett, and F. S. Yu, “Flagellin suppresses the inflammatory response and enhances bacterial clearance in a murine model of Pseudomonas aeruginosa keratitis,” Infection and Immunity, vol. 76, no. 1, pp. 89–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Laghaei, F. B. Hashemi, G. Irajian, F. Korpi, N. Amirmozafari, and B. Behrouz, “Immunogenicity and protective efficacy of Pseudomonas aeruginosa type a and b flagellin vaccines in a burned mouse model,” Molecular Immunology, vol. 74, pp. 71–81, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. F. Korpi, G. Irajian, M. Mahadavi et al., “Active immunization with recombinant PilA protein protects against Pseudomonas aeruginosa infection in a mouse burn wound model,” Journal of Microbiology and Biotechnology, 2015. View at Publisher · View at Google Scholar
  27. G. Goudarzi, M. Sattari, M. H. Roudkenar, M. Montajabi-Niyat, A. Zavaran-Hosseini, and K. Mosavi-Hosseini, “Cloning, expression, purification, and characterization of recombinant flagellin isolated from Pseudomonas aeruginosa,” Biotechnology Letters, vol. 31, no. 9, pp. 1353–1360, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Behrouz, N. Amirmozafari, N. Khoramabadi, M. Bahroudi, P. Legaee, and M. Mahdavi, “Cloning, expression, and purification of Pseudomonas aeruginosa flagellin, and characterization of the elicited anti-flagellin antibody,” Iranian Red Crescent Medical Journal, vol. 18, no. 6, article e28271, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. A. DiGiandomenico, J. Rao, K. Harcher et al., “Intranasal immunization with heterologously expressed polysaccharide protects against multiple Pseudomonas aeruginosa infections,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 11, pp. 4624–4629, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Farajnia, S. N. Peerayeh, A. Tanomand et al., “Protective efficacy of recombinant exotoxin A—flagellin fusion protein against Pseudomonas aeruginosa infection,” Canadian Journal of Microbiology, vol. 61, no. 1, pp. 60–64, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Yang, J. Gu, L. Yang et al., “Protective efficacy of the trivalent Pseudomonas aeruginosa vaccine candidate PcrV-OprI-Hcp1 in murine pneumonia and burn models,” Scientific Reports, vol. 7, no. 1, p. 3957, 2017. View at Publisher · View at Google Scholar
  32. A. Kamei, W. Wu, D. C. Traficante et al., “Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia,” The Journal of Infectious Diseases, vol. 207, no. 1, pp. 39–49, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. D. R. Chung, D. L. Kasper, R. J. Panzo et al., “CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism,” Journal of Immunology, vol. 170, no. 4, pp. 1958–1963, 2003. View at Publisher · View at Google Scholar
  34. Y. Li, Z. Wang, X. Liu, J. Tang, B. Peng, and Y. Wei, “X-ray irradiated vaccine confers protection against pneumonia caused by Pseudomonas aeruginosa,” Scientific Reports, vol. 6, p. 18823, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. J. B. Lyczak, C. L. Cannon, and G. B. Pier, “Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist,” Microbes and Infection/Institut Pasteur, vol. 2, no. 9, pp. 1051–1060, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. I. A. Holder, “Pseudomonas immunotherapy: a historical overview,” Vaccine, vol. 22, no. 7, pp. 831–839, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. L. D. Hazlett, S. A. McClellan, X. L. Rudner, and R. P. Barrett, “The role of Langerhans cells in Pseudomonas aeruginosa infection,” Investigative Ophthalmology & Visual Science, vol. 43, no. 1, pp. 189–197, 2002. View at Google Scholar
  38. S. Worgall, T. Kikuchi, R. Singh, K. Martushova, L. Lande, and R. G. Crystal, “Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells,” Infection and Immunity, vol. 69, no. 7, pp. 4521–7, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. M. L. Dunkley, R. L. Clancy, and A. W. Cripps, “A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung,” Immunology, vol. 83, no. 3, pp. 362–369, 1994. View at Google Scholar
  40. S. Shahrara, S. R. Pickens, A. M. Mandelin 2nd et al., “IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction,” Journal of Immunology, vol. 184, no. 8, pp. 4479–4487, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Aggarwal, N. Ghilardi, M. H. Xie, F. J. de Sauvage, and A. L. Gurney, “Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17,” The Journal of Biological Chemistry, vol. 278, no. 3, pp. 1910–1914, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. N. J. Kotloski, D. T. Nardelli, S. H. Peterson et al., “Interleukin-23 is required for development of arthritis in mice vaccinated and challenged with Borrelia species,” Clinical and Vaccine Immunology : CVI, vol. 15, no. 8, pp. 1199–1207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Misiak, M. M. Wilk, M. Raverdeau, and K. H. Mills, “IL-17-producing innate and pathogen-specific tissue resident memory γδ T cells expand in the lungs of Bordetella pertussis-infected mice,” Journal of Immunology, vol. 198, no. 1, pp. 363–374, 2017. View at Publisher · View at Google Scholar
  44. J. Liu, Y. Feng, K. Yang et al., “Early production of IL-17 protects against acute pulmonary Pseudomonas aeruginosa infection in mice,” FEMS Immunology and Medical Microbiology, vol. 61, no. 2, pp. 179–188, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Pan, R. Tan, M. Li et al., “IL17-producing γδ T cells may enhance humoral immunity during pulmonary Pseudomonas aeruginosa infection in mice,” Frontiers in Cellular and Infection Microbiology, vol. 6, p. 170, 2016. View at Publisher · View at Google Scholar
  46. E. Lockhart, A. M. Green, and J. L. Flynn, “IL-17 production is dominated by γδ T cells rather than CD4 T cells during mycobacterium tuberculosis infection,” Journal of Immunology, vol. 177, no. 7, pp. 4662–4669, 2006. View at Publisher · View at Google Scholar
  47. K. Shibata, H. Yamada, H. Hara, K. Kishihara, and Y. Yoshikai, “Resident Vδ1+ γδ T cells control early infiltration of neutrophils after Escherichia coli infection via IL-17 production,” Journal of Immunology, vol. 178, no. 7, pp. 4466–4472, 2007. View at Publisher · View at Google Scholar
  48. R. K. Braun, C. Ferrick, P. Neubauer et al., “IL-17 producing γδ T cells are required for a controlled inflammatory response after bleomycin-induced lung injury,” Inflammation, vol. 31, no. 3, pp. 167–179, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. C. L. Roark, P. L. Simonian, A. P. Fontenot, W. K. Born, and R. L. O'Brien, “γδ T cells: an important source of IL-17,” Current Opinion in Immunology, vol. 20, no. 3, pp. 353–357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. R. T. Sadikot, T. S. Blackwell, J. W. Christman, and A. S. Prince, “Pathogen-host interactions in Pseudomonas aeruginosa pneumonia,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 11, pp. 1209–1223, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Buret, M. L. Dunkley, G. Pang, R. L. Clancy, and A. W. Cripps, “Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha,” Infection and Immunity, vol. 62, no. 12, pp. 5335–5343, 1994. View at Google Scholar
  52. D. Drake and T. C. Montie, “Flagella, motility and invasive virulence of Pseudomonas aeruginosa,” Journal of General Microbiology, vol. 134, no. 1, pp. 43–52, 1988. View at Publisher · View at Google Scholar
  53. L. F. Neville, Y. Barnea, O. Hammer-Munz et al., “Antibodies raised against N-terminal Pseudomonas aeruginosa flagellin prevent mortality in lethal murine models of infection,” International Journal of Molecular Medicine, vol. 16, no. 1, pp. 165–171, 2005. View at Publisher · View at Google Scholar
  54. Y. Barnea, Y. Carmeli, E. Gur et al., “Efficacy of antibodies against the N-terminal of Pseudomonas aeruginosa flagellin for treating infections in a murine burn wound model,” Plastic and Reconstructive Surgery, vol. 117, no. 7, pp. 2284–2291, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. K. D. Smith, E. Andersen-Nissen, F. Hayashi et al., “Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility,” Nature Immunology, vol. 4, no. 12, pp. 1247–1253, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. K. G. Murthy, A. Deb, S. Goonesekera, C. Szabo, and A. L. Salzman, “Identification of conserved domains in Salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response In Vitro,” The Journal of Biological Chemistry, vol. 279, no. 7, pp. 5667–5675, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Ramphal, V. Balloy, J. Jyot, A. Verma, M. Si-Tahar, and M. Chignard, “Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin,” Journal of Immunology, vol. 181, no. 1, pp. 586–592, 2008. View at Publisher · View at Google Scholar
  58. M. Vijay-Kumar, H. Wu, R. Jones et al., “Flagellin suppresses epithelial apoptosis and limits disease during enteric infection,” The American Journal of Pathology, vol. 169, no. 5, pp. 1686–1700, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. A. B. Molofsky, B. G. Byrne, N. N. Whitfield et al., “Cytosolic recognition of flagellin by mouse macrophages restricts Legionella pneumophila infection,” The Journal of Experimental Medicine, vol. 203, no. 4, pp. 1093–1104, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Saha, F. Takeshita, T. Matsuda et al., “Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine,” Journal of Immunology, vol. 179, no. 2, pp. 1147–1154, 2007. View at Publisher · View at Google Scholar
  61. T. S. Murray, M. Egan, and B. I. Kazmierczak, “Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients,” Current Opinion in Pediatrics, vol. 19, no. 1, pp. 83–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Andersen-Nissen, K. D. Smith, R. Bonneau, R. K. Strong, and A. Aderem, “A conserved surface on Toll-like receptor 5 recognizes bacterial flagellin,” The Journal of Experimental Medicine, vol. 204, no. 2, pp. 393–403, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. V. L. Campodonico, N. J. Llosa, L. V. Bentancor, T. Maira-Litran, and G. B. Pier, “Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice,” Infection and Immunity, vol. 79, no. 8, pp. 3455–3464, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Sabharwal, S. Chhibber, and K. Harjai, “New possibility for providing protection against urinary tract infection caused by Pseudomonas aeruginosa by non-adjuvanted flagellin ‘b’ induced immunity,” Immunology Letters, vol. 162, no. 2, Part B, pp. 229–238, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Sabharwal, S. Chhibber, and K. Harjai, “Divalent flagellin immunotherapy provides homologous and heterologous protection in experimental urinary tract infections in mice,” International Journal of Medical Microbiology : IJMM, vol. 306, no. 1, pp. 29–37, 2016. View at Publisher · View at Google Scholar · View at Scopus